Infection and Drug Resistance (Feb 2022)
SARS-CoV-2 E484K Mutation Narrative Review: Epidemiology, Immune Escape, Clinical Implications, and Future Considerations
Abstract
Wan-Ting Yang,1,* Wei-Hsuan Huang,1,* Tsai-Ling Liao,2 Tzu-Hung Hsiao,2 Han-Ni Chuang,2 Po-Yu Liu1,3,4 1Division of Infection, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; 2Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan; 3Ph.D. Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan; 4Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan*These authors contributed equally to this workCorrespondence: Po-Yu LiuDivision of Infection, Department of Internal Medicine, Taichung Veterans General Hospital, 1650 Taiwan Boulevard Sect. 4, Taichung, 4070, Taiwan, Tel +886 4-23592525, Fax +886 4-2359-5046, Email [email protected]: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread rapidly over the world and claimed million lives. The virus evolves constantly, and a swarm of mutants is a now major concern globally. Distinct variants could have independently converged on same mutation, despite being detected in different geographic regions, which suggested it could confer an evolutionary advantage. E484K has rapidly emerged and has frequently been detected in several SARS-CoV-2 variants of concern. In this study, we review the epidemiology and impact of E484K, its effects on neutralizing effect of several monoclonal antibodies, convalescent plasma, and post-vaccine sera.Keywords: E484K, SARS-CoV-2 variant, coronavirus spike glycoprotein, SARS-CoV-2 convalescent sera treatment, monoclonal antibody, vaccine
